Latest Headlines

Latest Headlines

Venezuela hit in 2016 assumes negligible revenues for Merck

Merck said its guidance assumes negligible revenues from Venezuela in 2016, following similar warnings from Abbott Laboratories, Roche and Pfizer on fourth quarter earnings calls.

Currency woes overshadow Merck's 2015 growth in animal health

Merck reported that sales in its animal health unit fell 6% year over year to $830 million in the fourth quarter of 2015, which included a 14% negative impact from foreign exchange rates.

Blockbuster new launches coming from Intercept, Gilead and Merck: Reuters

The pharma industry heralded 11 new blockbusters in 2015, an act that's tough to follow. But while 2016 may not see quite that many, it's still on track to ring in 7 new therapies that have a shot at cracking the billion-dollar sales mark, a new analysis says.

Merck treads water in Q4 as Keytruda helps offset Remicade suffering

Merck & Co. took a one-two punch in the fourth quarter. Revenue from two top-selling franchises--Januvia and Remicade--slid, dragging overall sales below analyst estimates at $10.2 billion. One bright spot? A lower tax rate managed to boost Merck's earnings above analyst estimates at 93 cents per share.

NCI's Cancer Centers join in HPV vaccination push

All 69 of the United States' National Cancer Institute-designated centers have joined together to issue a statement urging an increase in HPV vaccinations, declaring the vaccines "tragically underused" and calling low uptake a "public health threat."

Merck, J&J, Pfizer consider joining Zika vaccine race

While the early entrants to the race for a Zika vaccine have been on the smaller side--think Hawaii Biotech, NewLink Genetics and Inovio Pharmaceuticals--the big guns are now joining in. Just one day after Sanofi announced a firm plan to develop a vaccine for the mosquito-borne disease, a parade of Big Pharmas has joined GlaxoSmithKline in "evaluating their technologies" for the potential of developing a Zika vaccine.

AbbVie guides cautious on Viekira with sharp competition and price cuts ahead in Japan

AbbVie CEO and Chairman Rick Gonzalez gave a good update on Japan for hepatitis C treatment Viekira which entered a market in December already served by Harvoni from Gilead Sciences and Bristol-Myers Squibb product Daklinza.

Sanofi's Brandicourt mulls pulling the plug on Merck JV: Bloomberg

Back in 1994, Merck and Pasteur Merieux Connaught--now Sanofi Pasteur--teamed up on a joint venture to develop and market vaccines in Europe. Now, as Sanofi chief Olivier Brandicourt reorganizes the French pharma's operations in a cost-cutting bid, the 21-year-old partnership could be on the chopping block.

Merck sets $54K list price for hep C combo as it preps for battle with Gilead, AbbVie

Industry watchers have long been speculating on how Merck would take on heavyweights Gilead and AbbVie when it priced its new hep C regimen. And now, they have their answer: Undercut them. Big-time.

Merck goes toe-to-toe with Gilead's hep C goliath, flags discount with blockbuster OK

Two years after Gilead Sciences triggered a market quake with a groundbreaking approval for Sovaldi, Merck is making a late entrance into the hep C market.